Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...
Phesgo has been approved by the EU for same indications as Herceptin/Perjeta – in combination with chemotherapy in early HER2-positive breast cancer (pre- and post-surgery) as well as for front ...
Hosted on MSN28d
HALO Gears Up to Report Q4 Earnings: Here's What You Should KnowHalozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s JNJ Darzalex and Roche’s Phesgo. The company’s top line comprises ...
Investor's Business Daily on MSN4mon
Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales ExpectationsPlease watch the video at Investors.com - How To Buy Stocks: Profit From Earnings Reports Using This Option Strategy The ...
Sales in the Pharmaceuticals Division grew 8% in 2024 to CHF 46.2 billion, driven by strong growth in demand for its key drugs, namely Vabysmo (severe eye diseases), Phesgo (breast cancer ...
The top-line growth was primarily driven by higher royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab) as well as an increase in milestone revenues ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback